

Effect of add-on transcranial alternating current stimulation (tACS) in  
major depressive disorder: a randomized controlled trial

ing ing ou<sup>a</sup> an i<sup>a</sup> u ang e<sup>a</sup> ui iu<sup>a</sup> uan eng<sup>a</sup>

---

---

---

Major depressive disorder is a common disease affecting more than 100 million people. It is a leading cause of disability worldwide and a major contributor to the overall global burden of disease. World Health Organization therefore the development of effective accessible interventions for it is a high priority for the implementation of public health first-line evidence-based treatment options for it include psycho pharmacology and psychotherapy. A recent meta-analysis of 10 studies of patients do not adequately respond to first-line treatments indicates generally in the combination of antidepressants and cognitive behavioral therapy so there is an urgent need for new treatment options.

Transcranial alternating current stimulation (tACS) is a neuromodulation technique that applies electrical currents through the scalp to regulate cortical excitability and spontaneous neuronal activity. It has been used for over a decade in different fields (for instance cognitive neuroscience) and it has only been applied in psychiatric clinical research in recent years. It represents most clinical studies on depression used the frequencies of 10 Hz or 20 Hz and stimulation sites selected in the frontal lobe. The studies also reported that a current of 2 mA and a frequency of 10 Hz can deliver electrical currents to deep brain tissues. It has also found that tACS (frequency) enhanced the levels of endorphins and neurotransmitters (including serotonin in the brainstem, norepinephrine and corticotropin-releasing hormone of endorphins and neurotransmitters changes are related to the neurobiological mechanisms for improving depressive symptoms.

The study examining tACS's role in treating depression evaluated the efficacy and safety of tACS as an effective alternative to antidepressant monotherapy in patients who were included in the study. The generalizability of its findings was limited, not a randomized controlled trial. The efficacy of tACS compared to placebo was not statistically significant and the dose of the antidepressants used in the study was not the antidepressant efficacy of different antidepressants. It is still unknown whether the combination of antidepressants and tACS could enhance the efficacy of antidepressants and reduce the gap in the first few sessions of antidepressant treatment. In addition to the antidepressant mechanism of tACS, the combined and current unclear.

Depression is related to a complex picture of altered brain oscillations. The resting-state low-frequency bands (delta, theta and alpha) in electroencephalogram (EEG) especially the alpha and theta bands in patients with depression in terms of either order or coherence. Moreover, the enhancement persisted even after an individual changed from an eye-closed to an eye-open state. In patients with the intermittent oscillator activity, the call in the alpha frequency band and the low global oscillations serve important functions in the healthy brain. The increased alpha oscillation in patients with depression represents a state of neuronal inactivity leading to disrupted affective processing. Researchers found that the left prefrontal cortex as indicated in the increased alpha frequency power during the processing of positive emotions in individuals with depression. Hence the elevated amplitude of left frontal alpha oscillations is theorized to correspond to a reduction in arousal. Positive experiences are associated with stimulation may produce a selective decrease in left frontal alpha oscillations to avoid images rated as positive.

Therefore, we conducted a double-blind study to evaluate the feasibility, safety and efficacy of tACS as a treatment for depressive symptoms of depression. To understand how it affects neuronal activity, we measured the alpha power changes as our secondary outcome using high-density EEG.

### 2.1. Study Design and participants

The double-blind randomized sham-controlled trial was performed at Beijing Normal University Medical Center from January to December. The trial received institutional review board approval and was performed in accordance with the principles originating in the Declaration of Helsinki and as reported in accordance with the guidelines. The study was registered on the ClinicalTrials.gov website before enrollment. The investigators and the participants were informed of the protocol during the study. All patients provided written informed consent prior to enrollment. The trial was completed on reaching the predetermined target enrollment numbers. After the trial all patients entered the depression cohort and were followed up for 6 weeks.

### 2.2. Sample size calculation

The primary endpoint is only one randomized controlled trial in estimating the effectiveness of tACS as an add-on to antidepressants in treating depression. However, we found that the effect size derived from this study was tremendous. The sample size was calculated based on the effect size as it would be too small to verify the effect statistically. Therefore, we used a conservative estimate of the effect size as considered the criteria for large effects to calculate our sample size instead. We applied to calculate the sample size. The set effect size = 0.5 (two-sided) = 0.05 = 0.05 and = 0.05 and found after calculation that each group would require approximately 100 patients. It is a drop-out rate. Therefore, the experimental and control groups should need approximately 100 patients each, making a total sample size of 200.

### 2.3. Inclusion/exclusion criteria

Participants were recruited through physician referrals and posters. The inclusion criteria were: being 18–65 years old, being diagnosed with a psychiatrist using the structured clinical interview for diagnostic and statistical manual of mental disorders (5th Edition) (DSM-5) indicating a total score of 10 or more on the Hamilton Rating Scale for Depression (HAM-D) and a minimum HAM-D depression score of 10 or more. They were not receiving antidepressant medications for the current depressive episode. They were able to understand and sign the informed consent form of the exclusion criteria. They were not currently taking any psychiatric medications, had no current or past history of seizures, epilepsy, alcohol abuse, central nervous system tumors or acute brain injury and infection. They were not at risk of suicide indicated a score of 10 or more on the Hamilton Rating Scale for Depression or a history of suicidal ideation. They were not used to electroconvulsive therapy (ECT) or modified electroconvulsive therapy (MECT). Transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS) or other neurostimulation treatments in the month before enrollment. They were not pregnant or breastfeeding. They did not have any organic diseases or were in an unstable condition because of an organic disease. The trial protocol specifically contains additional inclusion and all exclusion criteria is available in the supplement.

### 2.4. Randomization, concealment, and blinding

Computer-generated randomization schedule using random permuted blocks randomly assigned eligible patients to the active and sham treatment groups in a 1:1 ratio. The random number table containing randomization sequences was generated by the statistician. The statistician was not involved in conducting the trial. The second nurse (also not involved in conducting the trial) was

group assignment results generated from the random number table in identical sequential manner to a sealed envelope. Each patient received a sealed envelope at enrollment. In all on the patient's first day of enrollment or the day the patient received the first stimulation session the envelope contained group assignment information.

Double-blind randomization process and throughout the trial the active or sham groups as well as the active or sham stimulation devices were represented by the letters 'A' and 'B' for the device operators. The information on the letter assigned to a patient so that all individuals involved in the trial were blinded to the type of stimulation (active or sham) they were receiving. Also there was no difference between the active and sham stimulation devices in terms of appearance and the appearance influenced the patient's senses so the patient and the operator could not distinguish the instrument as the active stimulation device based on the appearance of the device or the subjective feelings of the patients. After statistical analyses in this study were completed unblinding was performed.

2.5. Procedures

Participants were asked to sit comfortably in reclining chairs while receiving the transcranial electrical stimulation administration. A research fellow, a clinical neurologist, administered trained nurses in accordance with standardized instructions. Two cm electrodes were placed on the forehead at Fz and in the international placement system. Two cm electrodes were placed on each side of the mastoid. The stimulation waveform includes ramp-up and ramp-down periods of 10 s and 10 s respectively. The waveform resembles a sine wave with an amplitude of 1 mA and is distributed equally from the frontal region to the mastoid areas.

All participants received sessions of stimulation at 10 min intervals. The sham condition had no active stimulation from onset to the end of the 10-min session as administered at a fixed time during the 10-min session. All participants were also asked to take 100 mg of escitalopram each day.

The study included the combined use of escitalopram throughout the 10-week period. All medications were taken orally after breakfast. Once daily the medication used in this study was 100 mg escitalopram tablets. Dose titration was performed. The researchers based on side effects and/or clinical course. The initial dose of escitalopram was 10 mg daily could be increased to 20 mg daily after 1 week based on the patient's condition. The dose could be further increased to 30 mg daily if necessary. Each increase in doses would be spaced a week apart and not less than a day apart.

2.6. EEG

Resting-state EEG data were collected at baseline and the 10-week follow-up using a 64-channel EEG system. The rain electrodes were positioned according to the standard international 10-20 system. The sampling frequency was 250 Hz and electrode impedance was less than 50 Ohms. Participants were asked to remain seated with their eyes closed for 10 minutes. In an condition participants were instructed to breathe on a cross-air. Participants also completed a face-ordered tasks. The results of the task are not presented here.

The EEG data were processed using the EEGLAB toolbox. The EEGLAB toolbox is a MATLAB-based tool for processing EEG data. The steps of EEG data processing were channel selection, removal of channels, and artifact removal. The segmentation of epochs into 1-s segments. The channels were re-referenced to the bilateral mastoid. The independent component analysis and independent component analysis were used to remove manual artifact removal after processing the independent component analysis of EEG data. The independent component analysis was estimated using the fast Fourier transform method and the power spectrum density.

Power spectrum density and power spectral density were calculated to compare the changes in EEG channels of the left frontal lobe. The selected and averaged to represent the power in the left frontal lobe.

2.7. Outcome measures

The primary endpoint was the change in the scores from baseline to the 10th treatment sessions. The secondary endpoints included clinical global impression of improvement, adverse effects, and the changes from baseline to the 10th treatment sessions. The scores on the Hamilton Depression Rating Scale, the Insomnia Severity Index, and the Somatic Symptom Scale were also measured. The primary endpoint was the change in the scores from baseline to the 10th treatment sessions. The secondary endpoints included clinical global impression of improvement, adverse effects, and the changes from baseline to the 10th treatment sessions. The scores on the Hamilton Depression Rating Scale, the Insomnia Severity Index, and the Somatic Symptom Scale were also measured.

The adverse effects were evaluated. The adverse effects included vital signs, clinical laboratory evaluations, and electrocardiogram parameters. Serious adverse events were defined as untoward medical occurrence that resulted in death, as life-threatening, at the time of the event, required inpatient hospitalization, resulted in persistent or significant disability.

2.8. Statistical analysis

The main analyses were completed on an intent-to-treat basis, meaning all randomized patients were included. Missing data for the scores were imputed using the last observation carried forward. The descriptive data at baseline were reported as the mean (standard deviation) or median and interquartile range for continuous variables and count (percentage) for categorical variables.

The primary endpoint was assessed using an independent-sample t-test based on data at the last observation carried forward. The imputation was performed to see sensitivity analyses for the primary outcome to assess the robustness of the results. The sensitivity analyses included multiple imputation for monotone missing data. We fitted a regression model from observed data and potential predictors (i.e., age, sex, baseline score, first episode) to generate imputed values. We used multiple imputations to impute values for each missing observation and combined estimates using Rubin's multiple imputation by chained equations. The analysis also performed to evaluate the effect of reductions in the scores on the 10th and the response rates differed between the two groups. The sensitivity analyses evaluated the effect of the interaction on the 10th scores. The linear mixed modeling was used on all available data. The interaction between the treatment group, visit, and their interaction (group x visit) was tested. The effects and the participant as a random effect.

The secondary outcome, the response rate, was assessed using the chi-square test. The reductions in the scores of each factor of the 10th and the scores of the 10th were compared using the Wilcoxon rank-sum test. The independent-sample t-test was used to compare the differences between the reductions in the scores on the 10th and the 10th in the active and sham groups. The correlation between the mean reduction in EEG and the mean reduction in the 10th total score from baseline to the 10th was evaluated. The Pearson correlation analysis.

The data were analyzed using the R software (R Foundation for Statistical Computing, Vienna, Austria). All values were two-sided and the differences were considered statistically significant when the p-value was < 0.05.

### 3.1. Participants

A total of 100 patients were assessed for eligibility and 66 patients met the inclusion criteria and were randomly allocated to the active treatment group (n = 33) or sham treatment group (n = 33) after randomization. Seven patients in the active treatment group were lost to follow-up and two patients in the active treatment group did not complete the study. Significant demographic and clinical characteristics are summarized in Table 1. More than half of the participants were female (56%). Mean values for other demographics included 50.1 ± 10.2 years for age, 17.8 ± 3.2 g/m for BMI, and 12 months for the duration of the recent episode. All participants were first episode and had a family history of mental disorders. All patients started at a dose of 1 mg/day of escitalopram and increased to 12 mg/day after 4 weeks. In total, 10 patients in each group increased to 12 mg/day after 4 weeks. In addition, one patient in the active treatment group did not take escitalopram and one patient in the sham treatment group maintained a dose of 12 mg/day.

### 3.2. Primary outcomes

In the intention-to-treat analysis, significant differences were found in the mean reduction of the HAM-D-21 scores at baseline (t = 2.1, P = 0.04). There were also statistically significant differences in the reduction of the HAM-D-21 scores between the two groups at 4 weeks and 8 weeks (t = 2.1, P < 0.05; t = 2.1, P = 0.04). Significant remission and reduction mean scores of all outcomes at all time points are shown in supplemental materials Table 1.


### 3.3. Secondary outcomes

Significantly more patients in the active treatment group (n = 20) responded (defined as a reduction of 50% or more from

### Basic information

	Active treatment	Sham treatment
Gender	Female (n = 18)	Female (n = 18)
Male	Male (n = 15)	Male (n = 15)
Educational level	Elementary school (n = 10)	Elementary school (n = 10)
High school	High school (n = 10)	High school (n = 10)
College	College (n = 10)	College (n = 10)
University	University (n = 10)	University (n = 10)
Marital status	Unmarried (n = 10)	Unmarried (n = 10)
Married	Married (n = 10)	Married (n = 10)
Monthly income (Chinese Yuan)	More than 1000 (n = 10)	More than 1000 (n = 10)
Less than 1000	Less than 1000 (n = 10)	Less than 1000 (n = 10)
Employment status	Employed (n = 10)	Employed (n = 10)
Unemployed	Unemployed (n = 10)	Unemployed (n = 10)
Family history of mental disorder	Family history of mental disorder (n = 10)	Family history of mental disorder (n = 10)
None	None (n = 10)	None (n = 10)
Obesity (BMI)	Obesity (n = 10)	Obesity (n = 10)
Not obese	Not obese (n = 10)	Not obese (n = 10)
Duration of current episode (months)	Duration of current episode (months) (n = 10)	Duration of current episode (months) (n = 10)
Less than 12	Less than 12 (n = 10)	Less than 12 (n = 10)
12 or more	12 or more (n = 10)	12 or more (n = 10)
Total score of HAM-D-21 at baseline	Total score of HAM-D-21 at baseline (n = 10)	Total score of HAM-D-21 at baseline (n = 10)
Less than 18	Less than 18 (n = 10)	Less than 18 (n = 10)
18 or more	18 or more (n = 10)	18 or more (n = 10)

n = number of patients; or mean (standard deviation) or median (interquartile range).





The mean reductions of the Hamilton Rating Scale for Depression (HAM-D) scores from baseline to weeks 2 and in the active and sham groups were 11.5 (range 7–15) and 12.5 (range 8–15), respectively. Higher scores indicate more severe depression symptoms. The error bars indicate the SEM. Missing data of the HAM-D scores for patients in the active and sham groups were imputed using the last observation carried forward (LOCF) method.

At baseline, the total score at baseline was compared between the sham group ( $n = 15$ ,  $P = 0.15$ ) and the active group ( $n = 15$ ,  $P = 0.15$ ). The difference was also observed at week 2 (active  $n = 15$ ,  $P = 0.15$ ; sham  $n = 15$ ,  $P = 0.15$ ) and week 4 (active  $n = 15$ ,  $P = 0.15$ ; sham  $n = 15$ ,  $P = 0.15$ ). Significant reductions in the scores on the depression and insomnia subscales of the HAM-D in the active group at week 2 were significantly larger ( $P < 0.05$ ) than the reductions in the scores on the depression, insomnia, and somatic subscales of the HAM-D in the active group. These significant differences were also observed for the active group as significant differences between the reductions in the HAM-D scores in the active and sham groups were

not statistically significant ( $P > 0.05$ ) for the sham group.

### 3.4. Sensitivity analysis

The results of the multiple imputation were consistent with those of the primary analysis. The results showed that the estimated mean HAM-D reduction in the active group was larger than in the sham group ( $t = 2.15$ ,  $P = 0.03$ ) at baseline. The per-protocol analysis also supported this result (see supplemental materials).


In addition, a mixed-effects model analysis of the treatment group, visit, and their interaction (group  $\times$  visit) as fixed effects and the participant as a random effect revealed a significant treatment group  $\times$  time interaction ( $F = 4.15$ ,  $P = 0.04$ ). The mean reduction in the HAM-D score from baseline to week 2 was significantly greater in the active group (least-squares mean reduction in the HAM-D score from baseline to week 2 was 11.5) than in the sham group (least-squares mean reduction in the HAM-D score from baseline to week 2 was 7.5) ( $F = 4.15$ ,  $P = 0.04$ ) (see supplemental materials).

### 3.5. Blinding integrity

To test the quality of the blinding in our study, we asked participants to all patients in the active stimulation group and patients who did not receive active stimulation (both the sham stimulation and the active stimulation) to guess whether they received active stimulation and were lost to follow-up in the active and sham stimulation groups. Most patients (12/15) and research assistants (12/15) who received active stimulation also guessed that there was no statistical difference between the two groups in the number of patients who guessed they received active or sham stimulations ( $F = 0.15$ ,  $P = 0.70$ ).

### 3.6. Mechanism exploration

Orthogonal heart rate as an effect in cardiac autonomic oscillations was assessed. The changes in resting-state alpha power at the electrode following the sham baseline alpha power were not different between the two groups. The combined changes in alpha power



The response rates at different visits in the active and sham groups were significantly higher in the active group than in the sham group. The response was defined as a reduction in the HAM-D rating scale for depression (range 7–15) indicating more severe depression symptoms. Missing data of the HAM-D scores for patients in the active and sham groups were imputed using the last observation carried forward (LOCF) method.

et een t e treatment grou s ut found no signi cant difference  
 ( u lementar materials ig en e conducted an in-de t  
 e lorator anal sis n t e acti e t grou e found a correlation  
 et een t e mean reduction of in e e-closed state EE and t e  
 mean reduction in t e - total score from aseline to ee (r  
 = P= lso in t e acti e t grou t e mean reduction of  
 from aseline to ee in e e-closed state EE as signi cantl  
 larger in t e res onders t an in t e non-res onders ( = =  
 n t e ot er and in t e s am t grou no consistent results  
 ere found ( ig similar anal sis of t e e-o en state did not  
 re eal an signi cant effect of t e stimulation on c anging al a o er  
 a en toget er our results indicate t at t as effecti e in targeting  
 al a oscillations in t e left frontal regions and t is c ange ad a  
 relations i it clinical s m toms

### 3.7. Safety

o serious ad erse e ents ere o ser ed in t is trial e re ort ed  
 general side effects in t e acti e t grou (com ared it t e s am  
 t grou included eadac e ( com ared it

it antide ressants t e a erage reduction rate of t e scores reac ed le ander et al randomi ed atients it into t ree stud grou s of - t - t and s am stimulation and administered one -min inter ention session eac da for consecuti e da s along it antide ressants e res onse rate of t e - t grou at ee as signi cantl ig ert ant e - and s am stimulation grou s suggesting t at - t ad a etter antide ressant ef cac e most relia le e idence in is for t it m n of t in drug-na e atients it s o ed a res onse rate of and a remission rate of after ee s of t treatment ic ere signi cantl ig ert an t e res onse and remission rates after s am stimulation ¶ and o e er t is stud onl included rst-e isode drug-na e atients and t e more signi cant treatment effect ma e e cause of t at not er studied t com ined it antide ressants in atients and found a romising clinical ef cac it a reduction of in t e scores in t e acti e grou and in t e s am grou at t e end of ee lt oug t is stud ad limitations and t e use of antide ressants as not limited t as an add-on to antide ressants ma e a good o tion for atients o need a fast effect long it ot er neuromodulations r also en ances t e clinical res onse to antide ressants and signi cantl accelerates t e alle iation of de ressi e s m toms in atients it stud of - ee r com ined it citalo ram found t at t e res onse rates in t e acti e grou ersus t e s am grou ere ersus at ee and ersus at ee stud of - ee r in com ination it aro etine found a res onse rate of and a remission rate of in t e acti e grou ic ere signi cantl ig ert ant ose in t e s am grou ¶ and at ee alt oug t ere as no signi cant difference at ee tudies of t as an add-on treatment to antide ressants also demonstrated t e s nergistic effect of com ination t era ne stud found t at artici ants recei ing ee s of t com ined it sertraline ad a res onse rate of and a remission rate of signi cantl ig ert ant ose in t e sertraline-onl grou ¶ and n anot er stud atients it ere di ided into t ree grou s -min -min and s am t com ined it sertraline fter ten da s of t stimulation t e -min -min and s am grou s s o ed res onse rates of and and remission rates of and res ecti el e im ro ement in de ressi e s m toms as more su stantial in t e acti e stimulation grou s and t e im ro ement in t e -min grou as signi cantl larger t an in t e -min grou n summar t is e cted to e an effecti e add-on antide ressant treatment com ara le to r and t o - ee er considering t at r and t a e een e aluated in large-scale multi-center trials ereas t as onl een studied in small-scale trials it s ould e noted t at t ere is a ris of false- ositi e ndings and our ndings need to e con rmed larger trials in t e future e - scores did not re eal an signi cant treatment ad antage in t e acti e t stimulation grou o er t e s am stimulation grou ome studies a e found t at atients scored t emsel es ig ert on self-re ort measures t an t e clinicians rated t em E lanations for t is enomenon include t e differences in t e focus of t e clinician and atient o erestimation of s m tom se erit t e atients ig le els of an iet need for a ro al ¶es e ciall social desira ilit and ig le els of self-transcendence ¶es e ciall self-forgetfulness urt ermore after com aring eac factor in t e - e found t at t e factors de ressed mood insomnia and somati on s o ed more ronounced im ro ements ereas t ese s m toms ere lig ter eig ted in t e - t is difference ma e art of t e reasons t e c anges in t e total score ere not signi cant re ious studies e amining t e concordance et een self-re ort and clinician-rated measures ere inconsistent and t is is t e main reason most clinical trials ould use ot self-re ort and clinician-rated measures as outcome instruments it t e latter ser ing as t e measurement tool for t e rimar outcome

e as also used to assess t e se erit of t e atient's de ressi e s m toms and t e degree of im ro ement e - scores at ee suggested t at t e t grou ad more im ro ement t an t e s am grou e results of t e - re ealed t e ositi e im act of t on t e o erall clinical im res sion of atients it lt oug t e is an instrument rel ing on t e su ecti e udgment of t e e aluators it ro ides im ortant information on t e effecti eness of treatment es e ciall for t e e aluation of ractical clinical signi cance e safet of using ig currents is a concern n t is stud ¶ of t e artici ants com leted t e - ee stud e dro out rate as lo er t an t e estimation of suggesting t at t e t used in t is stud as safe and ell tolerated ll atients ere follo ed u for ad erse e ents and most side effects in t is stud ere mild ¶some atients e er ienced di iness eadac e and da time slee iness ore im ortantl t ere as a difference et een t e ad erse e ents in t e t o grou s re ious studies did not re ort side effects of da time slee iness o e er e o ser ed r olonged da time slee iness t at as clearl related to t e treatment it slee iness eing t e most ronounced at t e end of t ¶alt oug it s ould e noted t at t is nding still needs to e alidated in future studies erefore it ma e necessar to notif atients o dri e e icles n addition no manic or o manic s m toms sei ures neurologic com lications o tical illusions deat s or ot er serious ad erse e ents ere o ser ed in our stud erall t e safet of t in com ination it antide ressants for t e treatment of as con rmed suggesting t at future clinical trials it t are feasi le e iological target of t e current stud as left frontal al a oscillations EE al a acti it is more ronounced it e es closed and al a o er as mmetr as een found to e more relia le it e es closed t an it e eso en e alteration of al a o er in our stud also occurred onl in t e e e-closed state is alteration as t oug t to re ect reduced neuronal acti it in t e left frontal lo e one of se eral e regions ere a normalities a e een found in rain imaging studies of de res sion ne article as e amined EE c anges after recei ing t in atients it it found t at - t resulted in a signi cant reduction in al a oscillations in t e left frontal region it e es closed ereas no c anges ere found it - t n addition - t s o ed etter antide ressant effects not er stud found t at t it indi iduali ed al a freuenc ¶ could reduce resting-state left frontal al a o er in atients it urt ermore t e reduction of left frontal al a oscillation t as s eci c for stimuli it ositi e alence ur stud also found a decrease in left frontal al a freuenc in atients ores onded to t e t treatment ut not in atients it no res onse e ot esi e t at t e antide ressant effect of t ma e related to t e decrease in left frontal al a o er e e act mec anism of t as not een determined studies a es o n t at t induces cortical oscillations entrainment and s i e-timing de endent lasticit tudies a e consistentl demonstrated t e locali ed o er en an cement after t and a e found t at immediate t after-effects led to an increase in resting-state al a o er e transient al a o er en an cement after a single t treatment ma e due to a stimulus dose t at is not suf cientl ersistent to induce long-term lasticit e increase in transient al a o er ma re ect neural induction of time-s nc roni ed cortical oscillations e ogenous stimuli ut e idence for long-term effects remains limited e found a decrease in al a o er after sessions of t ic is o osite to t e immediate effect suggesting t at re eated a lication of t ma lead to oscillator resetting ic in turn leads to a decrease in al a o er t roug a omeostatic mec anism roducing an antide ressant effect erefore t e results of t is stud once again suggested t at t e intrinsic regulation of al a oscillations ma e an im ortant mec anism for t e antide ressant effect of t is stud as some limitations irst e onl o ser ed t e ef cac in t e acute ase and e onl included a - ee follo -u ic is rat ers ort com ared to current est- ractice s in erefore

The maintenance effect still needs to be further investigated. Second, we used only theta stimulation and alpha stimulation. Different frequencies, currents, and electrode combinations is unknown. Third, we only compared the changes in left frontal alpha power and it is unclear whether the effects at other locations and frequencies changed. Also, all patients used antidepressants, which may be affected by the effects of the growing recognition of the presence of a normal oscillator dynamics in the pathogenesis of depression, as generated strong interest in the direct modulation of endogenous oscillations. Future studies on various forms of neuromodulation and EEG alterations in unmedicated patients are needed. Finally, the drop-out rates were higher in the sham group, which might be related to the lack of antidepressant effect in the group. Future studies should make efforts to reduce the drop-out rate in the sham group. In summary, although our trial provided preliminary evidence for the antidepressant effects of the larger long-term trials are needed to derive more reliable conclusions.

Our results suggest that the additional antidepressant effect of theta stimulation was significant and lasted for at least 2 weeks and combining theta stimulation with antidepressants is a feasible and effective approach for the treatment of depression. The antidepressant mechanism of theta stimulation and the reduction of theta power in the left frontal lobe are future research directions that may include exploring more appropriate treatment parameters of theta stimulation.

This study was funded by the National Natural Science Foundation of China (grant numbers: 81527809, 81527809, 81527809). The authors are grateful to all participants who took part in the study. We also thank the staff for their help during the study.

**Writing – review & editing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.  
**Original draft writing:** J. Zhou, C. Zhou, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang, L. Wang, X. Wang, Y. Wang.

The authors declare no competing interests.

We would like to thank the doctors and nurses for their generous support during the conduct of the study and all the patients and their families for participating in this trial. We also thank the financial support from the National Natural Science Foundation of China for supporting this transcranial alternating current stimulation research. We thank all the staff who worked on the study for their hard work.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.brs.2024.101111>

us ri edi isnie si ieren erg te art arden et al  
 cute and longer-term outcomes in depressed outpatients receiving one or several  
 treatment sessions: a randomized, controlled trial. *Journal of the American Academy of Psychiatry and  
 Behavioral Science*. 2014;59(1):1-8. [doi:10.1097/PSI.0b013e318275526b](https://doi.org/10.1097/PSI.0b013e318275526b).

ntal oros oreis aie erne aulus om arati el ea  
 after-effects of transcranial alternating current stimulation (tACS) on cortical  
 excitability in humans: a study using transcranial magnetic stimulation. *Neuroscience Letters*. 2014;560:  
 165-168. [doi:10.1016/j.nsl.2014.02.012](https://doi.org/10.1016/j.nsl.2014.02.012).

ars all elgadóttir ölle orn oosting slo oscillations during sleep  
 onset in memory: a study using transcranial magnetic stimulation. *Journal of Clinical Sleep Medicine*.  
 2014;10(12):1307-1314. [doi:10.5664/jcsm.4145](https://doi.org/10.5664/jcsm.4145).

ang ang ang ue eng un et al Effect of transcranial  
 alternating current stimulation for the treatment of chronic insomnia: a  
 randomized, double-blind, parallel-group, placebo-controlled clinical trial. *Journal of Clinical  
 Sleep Medicine*. 2014;10(12):1315-1323. [doi:10.5664/jcsm.4146](https://doi.org/10.5664/jcsm.4146).

El aman eic t errmann ulert ranscranial alternating current  
 stimulation (tACS) from basic mechanisms to clinical applications in psychiatry. *Journal of  
 Clinical Sleep Medicine*. 2014;10(12):1324-1331. [doi:10.5664/jcsm.4147](https://doi.org/10.5664/jcsm.4147).

Eur rc s c iatr lin eurosci ( )  
 le ander laga an ugo E ellin ustenerger uino et al  
 theta stimulation in the treatment of depression: a randomized, controlled trial. *Journal of Clinical  
 Sleep Medicine*. 2014;10(12):1332-1340. [doi:10.5664/jcsm.4148](https://doi.org/10.5664/jcsm.4148).

ou le- lind randomi ed ilot clinical trial targeting alpha oscillations in  
 transcranial alternating current stimulation (tACS) for the treatment of major  
 depressive disorder. *Journal of Clinical Sleep Medicine*. 2014;10(12):1341-1348. [doi:10.5664/jcsm.4149](https://doi.org/10.5664/jcsm.4149).

aller enner runoni ad erg alm amma transcranial  
 alternating current stimulation improves mood and cognition in patients with  
 major depressive disorder. *Journal of Clinical Sleep Medicine*. 2014;10(12):1349-1356. [doi:10.5664/jcsm.4150](https://doi.org/10.5664/jcsm.4150).

ang ang ue eng in u et al ranscranial alternating  
 current stimulation for treating depression: a randomized controlled trial. *Journal of Clinical  
 Sleep Medicine*. 2014;10(12):1357-1364. [doi:10.5664/jcsm.4151](https://doi.org/10.5664/jcsm.4151).

an ang ang ang ao uang et al Evidence of a large  
 current of transcranial alternating current stimulation directed to deep  
 regions of the brain. *Journal of Clinical Sleep Medicine*. 2014;10(12):1365-1372. [doi:10.5664/jcsm.4152](https://doi.org/10.5664/jcsm.4152).

e ede al gin o ale si c o a isoe ro oto  
 et al Effects for noninvasive transcranial electrostimulation of theta rhythm  
 and noradrenergic system activation for improvement of human social  
 interaction. *Journal of Clinical Sleep Medicine*. 2014;10(12):1373-1380. [doi:10.5664/jcsm.4153](https://doi.org/10.5664/jcsm.4153).

ite E ic ards e alin and related forms of subcortical electrical  
 stimulation in transcranial magnetic stimulation procedures in neuromodulation. *Journal of  
 Clinical Sleep Medicine*. 2014;10(12):1381-1388. [doi:10.5664/jcsm.4154](https://doi.org/10.5664/jcsm.4154).

egadoren 'donnell anius ou land aca e-asmonteil e role  
 of theta stimulation in the treatment of depression. *Journal of Clinical Sleep Medicine*.  
 2014;10(12):1389-1396. [doi:10.5664/jcsm.4155](https://doi.org/10.5664/jcsm.4155).

a erg rannan e ell il a a urin c innis et al  
 regional metabolic effects of theta stimulation in major depressive disorder: serial changes and  
 relations to clinical response. *Journal of Clinical Sleep Medicine*. 2014;10(12):1397-1404. [doi:10.5664/jcsm.4156](https://doi.org/10.5664/jcsm.4156).

iong uo an eigang et al Effect and safety of transcranial alternating  
 current stimulation combined with antidepressants in depressive disorders. *Journal of  
 Clinical Sleep Medicine*. 2014;10(12):1405-1412. [doi:10.5664/jcsm.4157](https://doi.org/10.5664/jcsm.4157).

i riani uru a a alanti aimani tinson ga a et al  
 theta stimulation and acceptance of antidepressant drugs for the acute  
 treatment of adults with major depressive disorder: a systematic review and  
 meta-analysis. *Journal of Clinical Sleep Medicine*. 2014;10(12):1413-1420. [doi:10.5664/jcsm.4158](https://doi.org/10.5664/jcsm.4158).

ingel urts ingel urts ltered structure of dynamic  
 electroencephalogram (EEG) oscillations in major depressive disorder. *Journal of Clinical  
 Sleep Medicine*. 2014;10(12):1421-1428. [doi:10.5664/jcsm.4159](https://doi.org/10.5664/jcsm.4159).

mart iru adi a erg ultimodal a roac es to de ne net or  
 oscillations in depression. *Journal of Clinical Sleep Medicine*. 2014;10(12):1429-1436. [doi:10.5664/jcsm.4160](https://doi.org/10.5664/jcsm.4160).

l ric rms EE iomar ers in major depressive disorder: discriminative  
 power and prediction of treatment response. *Journal of Clinical Sleep Medicine*. 2014;10(12):1437-1444. [doi:10.5664/jcsm.4161](https://doi.org/10.5664/jcsm.4161).

ort off o do resting state changes in depression translate into  
 social cognitive symptoms. *Journal of Clinical Sleep Medicine*. 2014;10(12):1445-1452. [doi:10.5664/jcsm.4162](https://doi.org/10.5664/jcsm.4162).

' atiotem oral s c o at olog ' urr in s c iatr ( )  
 e son iagara an EE frequency bands in psychiatric disorders: a  
 review of resting state studies. *Journal of Clinical Sleep Medicine*. 2014;10(12):1453-1460. [doi:10.5664/jcsm.4163](https://doi.org/10.5664/jcsm.4163).

uc ter oo unter ai or at esting-state quantitative  
 electroencephalogram reveals increased neurobiological connectivity in  
 depression. *Journal of Clinical Sleep Medicine*. 2014;10(12):1461-1468. [doi:10.5664/jcsm.4164](https://doi.org/10.5664/jcsm.4164).

ensen a a eri a ing functional architecture of an alpha  
 oscillation-gating mechanism. *Journal of Clinical Sleep Medicine*. 2014;10(12):1469-1476. [doi:10.5664/jcsm.4165](https://doi.org/10.5664/jcsm.4165).

limesc - and oscillations: attention and controlled access to stored  
 information. *Journal of Clinical Sleep Medicine*. 2014;10(12):1477-1484. [doi:10.5664/jcsm.4166](https://doi.org/10.5664/jcsm.4166).

armon- ones E a le nt e role of asymmetric frontal cortical activity in  
 depression and its differential motivation. *Journal of Clinical Sleep Medicine*. 2014;10(12):1485-1492. [doi:10.5664/jcsm.4167](https://doi.org/10.5664/jcsm.4167).

s c o siolog ( )  
 a idson anterior cerebral asymmetry and the nature of emotion. *Journal of Clinical  
 Sleep Medicine*. 2014;10(12):1493-1500. [doi:10.5664/jcsm.4168](https://doi.org/10.5664/jcsm.4168).

orld medical association declaration of Helsinki: ethical principles for medical  
 research involving human subjects. *Journal of Clinical Sleep Medicine*. 2014;10(12):1501-1504. [doi:10.5664/jcsm.4169](https://doi.org/10.5664/jcsm.4169).

outron o er lthman c ul a aud E tending t e  
 statement to randomized trials of non-pharmacologic treatment: explanation and  
 elaboration. *Journal of Clinical Sleep Medicine*. 2014;10(12):1505-1512. [doi:10.5664/jcsm.4170](https://doi.org/10.5664/jcsm.4170).

elorme a eig EE an o en source tool for analysis of single-trial  
 EEG dynamics including independent component analysis. *Journal of Clinical Sleep  
 Medicine*. 2014;10(12):1513-1520. [doi:10.5664/jcsm.4171](https://doi.org/10.5664/jcsm.4171).

eng ao illi s iu ai un et al Validity and reliability  
 of the Chinese Hamilton Depression Rating Scale. *Journal of Clinical Sleep Medicine*.  
 2014;10(12):1521-1528. [doi:10.5664/jcsm.4172](https://doi.org/10.5664/jcsm.4172).



in ang ong u en ing et al alidation of t e inese ersion  
of t e amilton rating scale for de ression in adults it e ile s E ile s e a  
i ou u u elia ilit and alidit of t e traditional inese  
ersion of t e - in ai anese atients it e ile s ormos ed ssoc  
iu iang ang u ng ari il ourne et al s c ometric  
ro erties of t e inese ersions of t e uic in entor of de ressi e  
m tomatolog - clinician rating ( - - and self-re ort ( - - ffect  
isord ( - -  
iu elia ilit and alidit of t e itts urg slee ualit inde inese ournal  
of s c iatr  
er g odd allal am ell ernardo et al e alidit of t e  
se erit and im ro ement scales as measures of clinical effecti eness suita le  
for routine clinical use E al lin ract ( - -  
il ening ur ec ec antsreiter E ad erg alm ranscranial  
alternating current stimulation for t e treatment of ma or de ression during  
regnanc s c iatr es -  
erlim an den E nde as ala is ig -fre uenc re etiti e transcranial  
magnetic stimulation accelerates and en ances t e clinical res onse to  
antide ressants in ma or de ression a meta-anal sis of randomi ed dou le- lind  
and s am-controlled trials lin s c iatr ( e -  
umi atta igonatti osa regni osa et al ranscranial